JP2019511526A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511526A5 JP2019511526A5 JP2018553357A JP2018553357A JP2019511526A5 JP 2019511526 A5 JP2019511526 A5 JP 2019511526A5 JP 2018553357 A JP2018553357 A JP 2018553357A JP 2018553357 A JP2018553357 A JP 2018553357A JP 2019511526 A5 JP2019511526 A5 JP 2019511526A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- oxo
- fluoro
- methyl
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 48
- 239000011780 sodium chloride Substances 0.000 claims description 48
- DNSISZSEWVHGLH-UHFFFAOYSA-N Butyramide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims description 23
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 23
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 16
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 201000005202 lung cancer Diseases 0.000 claims description 15
- UZWDCWONPYILKI-UHFFFAOYSA-N N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 claims description 12
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000005017 Glioblastoma Diseases 0.000 claims description 9
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 9
- 206010025650 Malignant melanoma Diseases 0.000 claims description 9
- 206010033128 Ovarian cancer Diseases 0.000 claims description 9
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 9
- 206010060862 Prostate cancer Diseases 0.000 claims description 9
- 206010039491 Sarcoma Diseases 0.000 claims description 9
- 201000001441 melanoma Diseases 0.000 claims description 9
- 208000002517 Adenoid Cystic Carcinoma Diseases 0.000 claims description 8
- 206010059352 Desmoid tumour Diseases 0.000 claims description 8
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims description 8
- 208000000172 Medulloblastoma Diseases 0.000 claims description 8
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims description 8
- 201000011231 colorectal cancer Diseases 0.000 claims description 8
- 201000006827 desmoid tumor Diseases 0.000 claims description 8
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 claims description 8
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 17
- -1 N- [5- (4-ethyl- Piperazin-1-ylmethyl) -pyridin-2-yl]-[5-fluoro-4- (7-fluoro-3-isopropyl-2-methyl-3H-benzimidazol-5-yl) -pyrimidin-2-yl] Chemical class 0.000 claims 13
- 150000001412 amines Chemical class 0.000 claims 3
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical group CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 241000321096 Adenoides Species 0.000 description 1
- 210000002534 Adenoids Anatomy 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 201000003741 gastrointestinal carcinoma Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 200000000025 progressive disease Diseases 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2(1H)-one Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021112726A JP7288482B2 (ja) | 2016-04-12 | 2021-07-07 | がんの処置のための、Notch阻害剤およびCDK4/6阻害剤の併用療法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662321311P | 2016-04-12 | 2016-04-12 | |
US62/321,311 | 2016-04-12 | ||
PCT/US2017/026134 WO2017180389A1 (en) | 2016-04-12 | 2017-04-05 | Combination therapy with notch and cdk4/6 inhibitors for the treatment of cancer |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021112726A Division JP7288482B2 (ja) | 2016-04-12 | 2021-07-07 | がんの処置のための、Notch阻害剤およびCDK4/6阻害剤の併用療法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019511526A JP2019511526A (ja) | 2019-04-25 |
JP2019511526A5 true JP2019511526A5 (US20070167479A1-20070719-C00034.png) | 2020-05-14 |
JP6911047B2 JP6911047B2 (ja) | 2021-07-28 |
Family
ID=58548919
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018553357A Active JP6911047B2 (ja) | 2016-04-12 | 2017-04-05 | がんの処置のための、Notch阻害剤およびCDK4/6阻害剤の併用療法 |
JP2021112726A Active JP7288482B2 (ja) | 2016-04-12 | 2021-07-07 | がんの処置のための、Notch阻害剤およびCDK4/6阻害剤の併用療法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021112726A Active JP7288482B2 (ja) | 2016-04-12 | 2021-07-07 | がんの処置のための、Notch阻害剤およびCDK4/6阻害剤の併用療法 |
Country Status (11)
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
MX2018012456A (es) | 2016-04-12 | 2019-03-07 | Lilly Co Eli | Terapia combinatoria con inhibidores notch y pi3k/mtor. |
MX2018012457A (es) | 2016-04-12 | 2019-03-07 | Lilly Co Eli | Terapia combinatoria con inhibidores notch y cdk4/6. |
SG11201810268YA (en) | 2016-05-20 | 2018-12-28 | Lilly Co Eli | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
CN117357638A (zh) | 2017-02-17 | 2024-01-09 | 弗雷德哈钦森癌症中心 | 用于治疗bcma相关癌症和自身免疫性失调的联合疗法 |
IL257225A (en) * | 2018-01-29 | 2018-04-09 | Yeda Res & Dev | Treatment of sarcoma |
CA3099479A1 (en) | 2018-05-06 | 2019-11-14 | Ayala Pharmaceuticals Inc. | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof |
WO2019226667A1 (en) * | 2018-05-25 | 2019-11-28 | Nantomics, Llc | Comprehensive molecular profiling with proteomic and genomic analyses |
CN112535686B (zh) * | 2019-09-20 | 2022-06-14 | 山东轩竹医药科技有限公司 | 激酶抑制剂的新用途 |
CN113880809B (zh) * | 2020-07-03 | 2022-10-18 | 盛世泰科生物医药技术(苏州)有限公司 | 一种嘧啶类衍生物及其制备方法和应用 |
WO2023109875A1 (en) * | 2021-12-16 | 2023-06-22 | Edigene Therapeutics (Beijing) Inc. | Biomarkers for colorectal cancer treatment |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ335583A (en) | 1996-12-23 | 2001-03-30 | Lilly Co Eli | Cycloalkyl, lactam, lactone and analogs, and pharmaceutical compositions |
EP1117778A2 (en) | 1998-10-02 | 2001-07-25 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Methods and compositions for inducing differentiation and apoptosis in cells that overexpress the notch protein |
CA3018525C (en) | 2005-07-01 | 2023-08-01 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
US8633179B2 (en) | 2007-03-13 | 2014-01-21 | The Trustees Of Columbia University In The City Of New York | Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids |
EP2178844A1 (en) | 2007-08-14 | 2010-04-28 | Eli Lilly & Company | Azepine derivatives as gamma-secretase inhibitors |
PA8852901A1 (es) * | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
WO2011060051A1 (en) | 2009-11-12 | 2011-05-19 | University Of Massachusetts | Methods for treating glioblastoma |
CN102085372A (zh) | 2009-12-04 | 2011-06-08 | 中国医学科学院基础医学研究所 | Notch通路抑制剂用于治疗mTOR活化导致的肿瘤的用途 |
JO3003B1 (ar) * | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
AR087107A1 (es) * | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
EP3003316B1 (en) | 2013-05-31 | 2020-07-22 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
RU2705795C2 (ru) | 2013-08-20 | 2019-11-12 | Мерк Шарп И Доум Корп. | Лечение рака комбинацией антагониста pd-1 и динациклиба |
US10092645B2 (en) | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
EP3280795B1 (en) | 2015-04-07 | 2021-03-24 | Novartis AG | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
MX2018012456A (es) | 2016-04-12 | 2019-03-07 | Lilly Co Eli | Terapia combinatoria con inhibidores notch y pi3k/mtor. |
MX2018012457A (es) | 2016-04-12 | 2019-03-07 | Lilly Co Eli | Terapia combinatoria con inhibidores notch y cdk4/6. |
SG11201810268YA (en) | 2016-05-20 | 2018-12-28 | Lilly Co Eli | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
ES2977556T3 (es) | 2016-08-31 | 2024-08-26 | Lilly Co Eli | Pauta posológica para el tratamiento de tumores sólidos |
EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
KR20200099137A (ko) | 2017-11-06 | 2020-08-21 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 요법 및 감마 세크레타제 억제제의 조합 |
-
2017
- 2017-04-05 MX MX2018012457A patent/MX2018012457A/es unknown
- 2017-04-05 AU AU2017249078A patent/AU2017249078B2/en active Active
- 2017-04-05 CA CA3020875A patent/CA3020875A1/en active Pending
- 2017-04-05 ES ES17717990T patent/ES2881801T3/es active Active
- 2017-04-05 EP EP17717990.0A patent/EP3442529B1/en active Active
- 2017-04-05 WO PCT/US2017/026134 patent/WO2017180389A1/en active Application Filing
- 2017-04-05 JP JP2018553357A patent/JP6911047B2/ja active Active
- 2017-04-05 RU RU2018138627A patent/RU2747788C2/ru active
- 2017-04-05 KR KR1020187032285A patent/KR102418765B1/ko active IP Right Grant
- 2017-04-05 CN CN201780036170.7A patent/CN109310684B/zh active Active
- 2017-04-05 US US16/093,123 patent/US11298362B2/en active Active
-
2021
- 2021-07-07 JP JP2021112726A patent/JP7288482B2/ja active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019511526A5 (US20070167479A1-20070719-C00034.png) | ||
JP7288482B2 (ja) | がんの処置のための、Notch阻害剤およびCDK4/6阻害剤の併用療法 | |
JP7278331B2 (ja) | がんの処置において使用するための、Notch阻害剤およびPI3K/mTOR阻害剤を用いた併用療法 | |
JP2013507415A5 (US20070167479A1-20070719-C00034.png) | ||
JP2019511529A5 (US20070167479A1-20070719-C00034.png) | ||
RU2014141362A (ru) | Комбинированная терапия пролиферативных нарушений | |
RU2017102319A (ru) | Прерывистое введение ингибитора mdm2 | |
KR101848131B1 (ko) | 저용량 이리노테칸염산염 수화물을 함유하는 항종양제 | |
JP2015524847A (ja) | 小細胞肺がんを治療するためのベンゾジアゼピン | |
JP2015517523A5 (US20070167479A1-20070719-C00034.png) | ||
JP2020510075A5 (US20070167479A1-20070719-C00034.png) | ||
JP2012522837A5 (US20070167479A1-20070719-C00034.png) | ||
TW201127384A (en) | Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent | |
RU2011150619A (ru) | Комбинация ингибитора фосфоинозитид-3-киназы и противодиабетического соединения | |
TW202131917A (zh) | 併用醫藥 | |
JP2011513429A (ja) | 改善された抗癌治療法 | |
KR20150136073A (ko) | 이리노테칸염산염 수화물을 함유하는 항종양제 | |
Navarro et al. | American Association for Cancer Research (AACR)-106th Annual Meeting. Philadelphia, Pennsylvania, USA-April 18-22, 2015 | |
US20200009104A1 (en) | Combination between trifluridine/tipiracil hydrochloride, an antitumor platinium complex, and an immune checkpoint modulator | |
US20110129467A1 (en) | Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents | |
Sharma et al. | New and potential therapies for the treatment of Breast Cancer: An update for oncologists | |
ES2703739T3 (es) | Combinación terapéutica que comprende un inhibidor aurora cinasa y un agente antineoplásico | |
NZ786609A (en) | Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer | |
NZ786604A (en) | Combination therapy with notch and cdk4/6 inhibitors for the treatment of |